MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, RNXT had -$2,270K decrease in cash & cash equivalents over the period. -$2,270K in free cash flow.

Cash Flow Overview

Change in Cash
-$2,270K
Free Cash flow
-$2,270K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-09-30
2025-06-30
Net loss
-2,912 -5,315
Stock-based compensation expense
349 633
Noncash lease expense
23 42
Depreciation expense
-1 2
Change in fair value of common warrant liability
-175 -234
Accounts receivable
-194 320
Inventory
272 -
Prepaid expenses
-80 102
Other current assets
-143 -15
Deferred offering costs
-0
Accounts payable
198 85
Accrued expenses
103 -489
Net cash used in operating activities
-2,270 -5,683
Purchase of property and equipment
0 2
Net cash used in investing activities
0 -2
Gross proceeds from equity financing
12,102 -
Issuance costs from equity financing
1,299 -
Proceeds from exercise of common warrants
0 25
Proceeds from exercise of stock options
0 17
Proceeds from equity financing, net of issuance cost
-10,803
Net cash provided by financing activities
0 10,845
Net increase in cash and cash equivalents
-2,270 5,160
Cash and cash equivalents at beginning of period
7,154 -
Cash and cash equivalents at end of period
10,044 -
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

RenovoRx, Inc. (RNXT)

RenovoRx, Inc. (RNXT)